LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Hematologic autoimmune disorders in the course of COVID-19: a systematic review of reported cases.

Taherifard, Erfan / Taherifard, Ehsan / Movahed, Hamed / Mousavi, Mohammad Reza

Hematology (Amsterdam, Netherlands)

2021  Volume 26, Issue 1, Page(s) 225–239

Abstract: ... which described 94 patients with COVID-19 who developed hematologic autoimmune disorder in their course ... of infection. Of these patients with COVID-19, the most common hematologic autoimmune disorder was ... immune thrombocytopenic purpura (55 cases) followed by autoimmune hemolytic anemia (22 cases). Other hematologic autoimmune ...

Abstract Objective: As COVID-19 is a new emerging disease, the hematological/immunological changes that develop in the infected patients remain unknown. This study aims to systematically review the hematologic autoimmune complications in these patients.
Method: Data from three online databases including Medline (via PubMed), Scopus and Web of Science were searched on 19 December 2020, and after excluding duplicate, irrelevant and inappropriate records, eligible documents were identified. Afterwards, information such as patients' history, presentations, paraclinical data, treatment course and outcome were extracted from the records.
Results: A total of 58 documents were considered to be eligible for data extraction which described 94 patients with COVID-19 who developed hematologic autoimmune disorder in their course of infection. Of these patients with COVID-19, the most common hematologic autoimmune disorder was immune thrombocytopenic purpura (55 cases) followed by autoimmune hemolytic anemia (22 cases). Other hematologic autoimmune disorders include antiphospholipid syndrome, thrombotic thrombocytopenic purpura, Evans syndrome and autoimmune neutropenia.
Conclusion: The current study would help us to always consider an autoimmune etiology for cases with abnormal hematologic finding which further lead to an appropriate treatment of the patients, especially when the symptoms present in about 1-2 weeks after the first manifestation of the infection symptoms. Maybe, at least in this pandemic, it should be recommended to evaluate patients with unexpected and unexplained decrease in their hemoglobulin or platelet count for COVID-19. Another challenging issue is the treatment options. Given the multiorgan involvement and multifaceted nature of the infection, an individualized approach should be taken for each patient.
MeSH term(s) Anemia, Hemolytic, Autoimmune/blood ; Anemia, Hemolytic, Autoimmune/etiology ; Antiphospholipid Syndrome/blood ; Antiphospholipid Syndrome/etiology ; Autoimmune Diseases/blood ; Autoimmune Diseases/etiology ; COVID-19/blood ; COVID-19/complications ; Hematologic Diseases/blood ; Hematologic Diseases/etiology ; Humans ; Neutropenia/blood ; Neutropenia/etiology ; Purpura, Thrombocytopenic, Idiopathic/blood ; Purpura, Thrombocytopenic, Idiopathic/etiology ; Purpura, Thrombotic Thrombocytopenic/blood ; Purpura, Thrombotic Thrombocytopenic/etiology ; SARS-CoV-2/isolation & purification ; Thrombocytopenia/blood ; Thrombocytopenia/etiology
Language English
Publishing date 2021-02-17
Publishing country England
Document type Journal Article ; Systematic Review
ZDB-ID 1341428-8
ISSN 1607-8454 ; 1024-5332 ; 1024-5340
ISSN (online) 1607-8454
ISSN 1024-5332 ; 1024-5340
DOI 10.1080/16078454.2021.1881225
Shelf mark
Zs.A 4538: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top